Tune Therapeutics

Mastering the epigenome, unlocking complex disease.

Founded 2020

Seattle, United States 67 employees Series B Total: $215.00M Biotechnology

General Information

Company Name Tune Therapeutics

Founded Year 2020

Location

Seattle, United States

Founders / Decision Makers

Employees 67

Industries Biotechnology

Funding Stage Series B

Business Model B2B, B2D, Platform

Revenue Model Licensing, Service Fee, Performance Based

Social

BounceWatch is an independent company data service, not affiliated with Tune Therapeutics. To contact Tune Therapeutics, visit tunetx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Tune Therapeutics compare?

A PDF of Tune Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Tune Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Tune Therapeutics on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

United States Market

Market Signals All Companies

Biotechnology

Industry Signals All Companies in United States

Tune Therapeutics Alternatives

All Signals Trend Reports

About Tune Therapeutics

Tune Therapeutics, with its slogan "Mastering the epigenome, unlocking complex disease," is making significant strides in the biotechnology industry since its founding in 2020. Headquartered in the United States, the company is at the forefront of epi-therapeutic medicine development. Its proprietary platform, TEMPO, offers a novel approach to genetic tuning by adjusting gene expression levels without altering the DNA permanently. This method presents a transformative potential in treating complex diseases such as cancer, genetic disorders, and conditions related to aging, broadening the scope of genetic medicine.

The company recently secured a $175.00M Series B investment on January 1, 2025, with notable participation from investors such as NEA, Regeneron Pharmaceuticals, Yosemite, and Hevolution. With this substantial backing, Tune Therapeutics is well-positioned to advance its research and development efforts, poised to make a considerable impact on healthcare by addressing numerous currently incurable diseases.

Business keywords: epigenomics, epigenetic programming, epi-therapeutic medicines, gene expression modulation, cell fate modulation, genetic medicine, cancer therapeutics, genetic disease treatment, aging reversal therapies, complex disease treatment, cell therapy, gene therapy, biotechnology innovation, temporal gene expression control, precision medicine

Services & Products

Epigenetic silencing for diseases like Hepatitis B

Regulation of gene activity without altering DNA sequence

Developing gene, cell, and regenerative therapies

Target Customers

Healthcare providers Biotech researchers Patients with chronic or age-related diseases Clinical trial participants

Funding Rounds & Investors (2)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	$175.00M	4	NEA, Regeneron Pharmaceuticals +2	01 Jan 2025
Series A	$40.00M	-		01 Dec 2021

Latest News

View All

Ipsen is no longer advancing Sutro’s ADC; Layoffs at Tune Therapeutics

Endpoints.news Aug 08, 2025

Tech Moves: Starbucks names CFO; Avanade bolsters C-suite; Tune Therapeutics gets CEO

Geekwire.com Mar 04, 2025

Duke professor-led biotech company raises $175 million to advance epigenome editing therapy clinical... — Dukechronicle.com

Duke professor-led biotech company raises $175 million to advance epigenome editing therapy clinical trials

Dukechronicle.com Jan 31, 2025

Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Edit... — Biospace.com

Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs

Biospace.com Jan 13, 2025

JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more

Fiercebiotech.com Jan 13, 2025

Seattle biotech company raises the first local 9-figure round of 2025

Bizjournals.com Jan 12, 2025

Tune Therapeutics Alternatives & Competitors

View All Alternatives

Tune Therapeutics vs

Epicrispr Biotechnologies United States

The future of genetic medicine is epic.

Series B

53 employees

Biotechnology

Compare Tune Therapeutics vs Epicrispr Biotechnologies

Tune Therapeutics vs

Graphite Bio United States

Creating a future where the word 'incurable' no longer exists.

Acquired

2 employees

Biotechnology

Compare Tune Therapeutics vs Graphite Bio

Tune Therapeutics vs

Kite Pharma United States

At Kite, a Gilead Company, our singular focus is cell therapy to treat and cure cancer.

Acquired

4013 employees

Biotechnology, Health Care

Also compare with:

Be Biopharma View all alternatives

FAQ About Tune Therapeutics

Mastering the epigenome, unlocking complex disease.

Tune Therapeutics was founded in 2020.

Tune Therapeutics is headquartered in Seattle, United States.

Tune Therapeutics operates in Biotechnology. Its work centres on epigenomics, epigenetic programming, epi-therapeutic medicines and gene expression modulation. Its customers include Healthcare providers, Biotech researchers and Patients with chronic or age-related diseases.

Tune Therapeutics has a B2B, B2D and Platform business model. Its revenue comes from Licensing, Service Fee and Performance Based.

Tune Therapeutics has approximately 67 employees.

Tune Therapeutics has completed 2 funding rounds, raising a total of $215.00M. The latest funding stage is Series B.

Tune Therapeutics offers: Epigenetic silencing for diseases like Hepatitis B, Regulation of gene activity without altering DNA sequence, Developing gene, cell, and regenerative therapies.

Top alternatives and competitors to Tune Therapeutics include Epicrispr Biotechnologies, Graphite Bio, Kite Pharma, Cartesian Therapeutics, Thymmune Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Tune Therapeutics and Epicrispr Biotechnologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Tune Therapeutics, https://bouncewatch.com/company/tune-therapeutics, updated 3 July 2026. When citing, please name BounceWatch and link this page.